Hologic traded at $75.10 this Wednesday February 11th, decreasing $0.05 or 0.07 percent since the previous trading session. Looking back, over the last four weeks, Hologic lost 0.32 percent. Over the last 12 months, its price rose by 18.21 percent. Looking ahead, we forecast Hologic to be priced at 72.51 by the end of this quarter and at 66.04 in one year, according to Trading Economics global macro models projections and analysts expectations.
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products focused on women's health and well-being through early detection and treatment. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Diagnostics segment offers a range of diagnostics products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a portfolio of solutions for breast cancer care for radiology, pathology and surgery. The GYN Surgical segment offers a range of products, including its NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System as well as its Fluent Fluid Management system. The Skeletal Health segment offers products such as the Horizon DXA, a dual energy x-ray system, which evaluates bone density and performs body composition assessments, and the Fluoroscan Insight FD mini C-arm.